As one of 10 of the available glucagon-like peptide 1 receptor agonists (GLP-1 RAs), semaglutide is branded as Ozempic, Rybelsus, and Wegovy. Semaglutide was first developed in 2012 for use in the management of type 2 diabetes, but starting in 2018, it began to be used worldwide. Since that time, research into semaglutide and other GLP-1 RAs has exploded, with numerous new applications being explored. High patient demand for semaglutide coupled with high prices have made treatment less accessible for many patients, even as potential therapeutic uses increase. A recent survey suggests that many clinicians are likely to encounter patients asking about GLP-1 RAs despite their scarcity and cost.
Test your knowledge about semaglutide and other GLP-1 RAs, including indications, contraindications, and adverse effects, with a short quiz.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Richard H. Sinert. Fast Five Quiz: Semaglutide - Medscape - Oct 25, 2023.